Financial News
KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
By:
Business Wire
April 17, 2025 at 21:08 PM EDT
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.
The release was issued in error by Aditxt, Inc.
A replacement release will not be issued at this time.
Contacts
Aditxt, Inc.
Corporate Communications
Jeff Ramson, PCG Advisory, Inc.
T: 646-863-6893
contactus@aditxt.com
More News
View More
MNDY Stock Has a Case of the Mondays—Buy Before the Rebound
August 11, 2025
Via MarketBeat
Tickers
MNDY
IPO Market Stays Hot With These 2 Debuting Stocks
August 11, 2025
Taiwan Semiconductor Stock: Own It, Don't Trade It
August 11, 2025
4 Stocks That May Get a Big Earnings Bump This Week
August 11, 2025
Via MarketBeat
Why SoundHound AI's Earnings Show the Stock Can Move Higher
August 11, 2025
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.